Equities

Sutro Biopharma Inc

Sutro Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.89
  • Today's Change-0.03 / -0.77%
  • Shares traded487.62k
  • 1 Year change+9.58%
  • Beta1.1814
Data delayed at least 15 minutes, as of Sep 20 2024 20:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy4
Outperform6
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Sutro Biopharma Inc have a median target of 11.50, with a high estimate of 20.00 and a low estimate of 5.00. The median estimate represents a 193.37% increase from the last price of 3.92.
High410.2%20.00
Med193.4%11.50
Low27.6%5.00

Earnings history & estimates in USD

On Aug 13, 2024, Sutro Biopharma Inc reported 2nd quarter 2024 losses of -0.590 per share. This result exceeded the -0.79 consensus loss of the 10 analysts covering the company and exceeded last year's 2nd quarter results by 7.81%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+5.67%
Sutro Biopharma Inc reported annual 2023 losses of -1.78 per share on Mar 25, 2024.
Average growth rate-12.60%
More ▼

Revenue history & estimates in USD

Sutro Biopharma, Inc. had 2nd quarter 2024 revenues of 25.71m. This bettered the 21.02m consensus of the 10 analysts covering the company. This was 102.82% above the prior year's 2nd quarter results.
Average growth rate+160.89%
Sutro Biopharma, Inc. had revenues for the full year 2023 of 153.73m. This was 126.84% above the prior year's results.
Average growth rate+45.29%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.